Unlock stock picks and a broker-level newsfeed that powers Wall Street.

OTC Markets EXMKT - Delayed Quote USD

Curative Biosciences, Inc. (CBDX)

Compare
0.0001
0.0000
(0.00%)
At close: April 18 at 4:00:00 PM EDT
Loading Chart for CBDX
  • Previous Close 0.0000
  • Open 0.0001
  • Bid --
  • Ask --
  • Day's Range 0.0001 - 0.0001
  • 52 Week Range 0.0001 - 0.0015
  • Volume 4,700
  • Avg. Volume 752
  • Market Cap (intraday) 9.338M
  • Beta (5Y Monthly) -17.87
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0000
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Curative Biosciences, Inc. focuses on developing and commercializing therapeutics using hemp-derived Cannabidiol. It intends to manufacture and market natural health products and operate in the medical cannabis industry. The company was formerly known as Amaize Beverage Corporation and changed its name to Curative Biosciences, Inc. in August 2017. Curative Biosciences, Inc. was founded in 2009 and is based in Miami, Florida.

--

Full Time Employees

June 30

Fiscal Year Ends

Recent News: CBDX

View More

Performance Overview: CBDX

Trailing total returns as of 4/18/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CBDX
0.00%
S&P 500 (^GSPC)
10.18%

1-Year Return

CBDX
93.33%
S&P 500 (^GSPC)
5.42%

3-Year Return

CBDX
83.33%
S&P 500 (^GSPC)
20.29%

5-Year Return

CBDX
99.96%
S&P 500 (^GSPC)
83.77%

Compare To: CBDX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CBDX

View More

Valuation Measures

Annual
As of
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -3,843.90%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -518.1k

  • Diluted EPS (ttm)

    -0.0000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    982

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: CBDX

View More

Company Insights: CBDX

Research Reports: CBDX

View More

People Also Watch